HK inno.N begins selling reflux treatment in Peru
Published: 16 Oct. 2023, 18:06
- SHIN HA-NEE
- shin.hanee@joongang.co.kr
HK inno.N has begun selling its K-CAB tablet, a gastroesophageal reflux disease treatment, in Peru, the pharmaceutical company said Monday.
The drug was made available in the market starting Oct. 12, under the brand Ki-CAB. The local sales of the drug in Peru as well as 16 other Latin American countries are being handled by Laboratorios Carnot.
Peru is K-CAB’s second destination for market release in the region following Mexico, where HK inno.N began selling the drug in May, and seventh outside Korea.
K-CAB is currently available in China, Mongolia, Philippines, Mexico, Indonesia, Singapore and Peru, through technology or product exports.
HK inno.N has signed technology or product export contracts for K-CAB with a total of 35 countries overseas, such as the United States, China and 18 Latin American nations including Brazil.
BY SHIN HA-NEE [shin.hanee@joongang.co.kr]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)